GlassScriptPhysician profile
Timothy W Mcclellan
NPI 1447238670
$6,489.75
in general payments reported to CMS, 2019-2025
35 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $266 · 2022: $1,149 · 2023: $1,310 · 2024: $1,411 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,138 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,137.79 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,313.46 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $683.64 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $473.56 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $465.26 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $333.44 | 2019-2025 | Dificid, Bridion |
| Regeneron Healthcare Solutions, INC. | $255.14 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $214.69 | 2022-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $163.17 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $119.37 | 2020-2025 | Linzess |
| Celgene Corporation | $117.61 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $111.52 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $108.80 | 2019-2025 | Ocaliva |
| Ethicon US, LLC | $107.73 | 2019 | |
| Lilly USA, LLC | $106.86 | 2024-2025 | Omvoh |
| Pfizer INC. | $103.62 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $100.97 | 2025 | Watchman Flx, Cre Pro, Koala |
| Gilead Sciences, INC. | $83.43 | 2019-2024 | |
| Ardelyx, INC. | $71.62 | 2022-2023 | Ibsrela |
| Celltrion USA INC. | $70.01 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $51.96 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $50.76 | 2022 | |
| Genzyme Corporation | $49.56 | 2022 | |
| Braintree Laboratories, INC. | $44.26 | 2022-2025 | Suflave |
| Fresenius Kabi USA, LLC | $44.05 | 2023 | Smoflipid |
| Organon LLC | $38.14 | 2022-2023 | Hadlima |
| Ferring Pharmaceuticals INC. | $36.50 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $35.86 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $23.96 | 2019 | |
| Vivus LLC | $23.83 | 2024 | Qsymia |
| Amgen INC. | $21.92 | 2023 | Amjevita, Avsola |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 2022 | |
| Allergan, INC. | $12.64 | 2019 | |
| Redhill Biopharma INC. | $11.94 | 2020 | |
| Romark Laboratories, Lc | $11.55 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $9.43 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.